Page 56 - Amgen News Today

Payal Kohli, MD, discusses how recent advancements have changed conversations surrounding modifiable cardiovascular risk and what it means for practitioners.

Eli Lilly and Novo are leading now, but there are multiple drug candidates waiting in the wings that could disrupt that duopoly in the future.

Amgen (NASDAQ: ) stock is trending and up about 12% as of this writing. The shares are rallying after the drugmaker’s CEO said he was encouraged by…

Amgen’s update fueled concerns about potential new competition in the weight loss drug market, sending shares of Novo Nordisk and Eli Lilly lower.

Amgen goes all in on injectable obesity drug as it scraps early-stage pill Amgen said Thursday that it will no longer develop an early-stage obesity pill, and…

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

Recent regulatory warnings could mean that four in five patients with RA may not be prescribed JAK inhibitors unless there is no other alternative.

The U.S. economy added just 175,000 jobs and the unemployment rate rose to 3.9% in April

Wall Streets main indexes were set to open higher on Friday after a softer-than-expected jobs report revived hopes of the Federal Reserve cutting interest rates this year, while gains in Apple and...